Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
SGX Pharmaceuticals, Inc. |
---|---|
Information provided by: | SGX Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00104468 |
This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™ whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish the recommended infusion schedule of Troxatyl™.
Condition | Intervention | Phase |
---|---|---|
Acute Myelogenous Leukemia |
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic) |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia |
Estimated Enrollment: | 50 |
Study Start Date: | April 2003 |
Study Completion Date: | June 2007 |
Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
Cornell Medical College, New York Presbyterian | |
New York, New York, United States, 10021 | |
United States, Texas | |
MD Anderson | |
Houston, Texas, United States, 77030 |
Study ID Numbers: | SPD758-110 |
Study First Received: | February 28, 2005 |
Last Updated: | January 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00104468 |
Health Authority: | United States: Food and Drug Administration |
Single-arm, open-label, multi-center, dose escalation, continuous infusion, multi-dose, acute myeloid leukemia Acute myelogenous leukemia (AML) that has been refractory to prior therapy and/or is unlikely to benefit from known therapies |
Troxacitabine Leukemia Acute myelogenous leukemia |
Leukemia, Myeloid Leukemia, Myeloid, Acute Acute myelocytic leukemia |
Anti-Infective Agents Neoplasms Anti-HIV Agents Neoplasms by Histologic Type Anti-Retroviral Agents |
Antineoplastic Agents Therapeutic Uses Antiviral Agents Pharmacologic Actions |